This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
by Zacks Equity Research
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
by Zacks Equity Research
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
by Zacks Equity Research
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
by Zacks Equity Research
Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.
Intellia Focuses on Pipeline Development Amid Stiff Competition
by Zacks Equity Research
Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
by Urmimala Biswas
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.
Top Stock Reports for Tesla, Home Depot & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, Inc. (HD) and Boston Scientific Corp. (BSX), as well as two micro-cap stocks Frequency Electronics, Inc. (FEIM) and Bridger Aerospace Group Holdings, Inc. (BAER).
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
by Zacks Equity Research
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
by Zacks Equity Research
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
by Zacks Equity Research
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TSVT Up on Acquisition Agreement With BMY for $286 Million
by Zacks Equity Research
2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
by Zacks Equity Research
Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
by Zacks Equity Research
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
by Zacks Equity Research
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales
by Zacks Equity Research
BAYRY's fourth-quarter earnings match expectations. Revenues top estimates, driven by the strong performance of its pharmaceutical business.
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
by Zacks Equity Research
The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
by Zacks Equity Research
Merck, Sanofi, Regeneron and Ionis are included in this Analyst Blog.
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
by Kinjel Shah
EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
by Zacks Equity Research
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
by Zacks Equity Research
ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.